Fabry Disease Market Size in the 7MM is Estimated to Exceed USD 3,898.0 Million by 2035

How big is the Fabry disease market?

The 7 major fabry disease markets reached a value of USD 1,637.7 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 3,898.0 Million by 2035, exhibiting a growth rate (CAGR) of 8.20% during 2025-2035.

The Fabry disease market is growing rapidly because of treatment options and the awareness and diagnostic methods being developed.

What is Fabry disease?

Fabry disease is a rare genetic disorder caused by the deficiency of the enzyme alpha-galactosidase A, which accumulates harmful substances in the cells of the body, affecting different organs.

The expansion of the market is mainly attributable to the growing adoption of enzyme replacement therapies (ERTs). ERTs, including agalsidase beta and pegunigalsidase alfa, have formed the backbone for treating Fabry disease by decreasing the cellular accumulation of globotriaosylceramide (Gb3). Newly approved ERTs with greater efficacy and shorter infusion times have improved compliance and outcomes for those patients.

Request for a sample of this report: https://www.imarcgroup.com/fabry-disease-market-report/requestsample

With the rise of oral chaperone therapies, patients with amenable mutations might have a more comfortable treatment option, as these stabilize the defective enzyme, improving its activity while reducing substrate accumulation. An increasing pipeline for such treatments reflects well for the market's future.

Similarly, the advent of diagnostic techniques and technologies has strengthened the market growth. The European Union has taken the bold step of mandating several newborn screening programs, whereas genetic testing is available since early diagnosis through these approaches is an intervention point especially useful in preventing irreversible organ damages with progressive Fabry disease.

Regarding geography, North America holds sway over the Fabry disease market because of advanced healthcare facilities, high awareness levels, goodwill reimbursement policies, etc. However, the fast-growing areas in Fabry disease treatment markets are to be Asia-Pacific regions, by virtue of a rise in healthcare expenditure, rising awareness for Fabry disease, and expansion of gene diagnostic centers.

The market growth is also supported by the continuous research and development activities. Several companies are working toward gene therapies that will offer a chance for a one-time treatment to reverse the genetic defect. Any changes arising from such inventions will lay a new foundation in the treatment of Fabry disease.

Ask the Analyst for Customization and Get Full Insights with TOC: https://www.imarcgroup.com/request?type=report&id=30204&flag=E

The report also provides a detailed analysis of the current fabry disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Competitive Landscape With Key Players:

The competitive landscape of the fabry disease market has been studied in the report with the detailed profiles of the key players operating in the market.

Sanofi
Chiesi/Protalix Biotherapeutics
Amicus Therapeutics
uniQure
AceLink Therapeutics

IMARC Group Offers Other Reports:

Autism Spectrum Disorder Market https://www.imarcgroup.com/autism-spectrum-disorder-market

Amblyopia Market https://www.imarcgroup.com/amblyopia-market

Gastroesophageal Reflux Disease Market https://www.imarcgroup.com/gastroesophageal-reflux-disease-market

Surgical Site Infections Market https://www.imarcgroup.com/surgical-site-infections-market

Adeno-associated Virus Gene Therapy Market https://www.imarcgroup.com/adeno-associated-virus-gene-therapy-market

Contact US:

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145

About Us:

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services.

IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

This release was published on openPR.